ABSTRACT Of a series of five newly synthesized 2'-deoxyuridine derivatives, including 5 (1-chlorovinyl)-dUrd, (E--(2-bromovinyl)-dUrd, and (E)5-(2-iodovinyl).dUrd, the last two compounds were found to exert a marked inhibitory effect on the replication of herpes simplex virus type 1 [ID50 (mean inhibitory dose), 0.004-0.02 ;tg/mll.
highly selective in their anti-herpes activity in that they did not affect the growth or metabolism of the host (primary rabbit kidney) cells unless drug concentrations were used that were 5,000-to 10,000-fold greater than those required to inhibit virus multiplication. In this sense (E-5-2-bromovinyl).dUrd and (E)5-2-iodovinyl)-dUrd proved more selective in their activity against herpes simplex virus type 1 than all other anti-herpes compounds that have been described so far. In animal model systems (namely, cutaneous herpes infections of athymic nude mice), (E)-5(2-bromovinyl)-dUrd suppressed the development of herpetic skin lesions and mortality therewith associated, whether the compound was administered topically or systemically. Under the same conditions, the standard anti-herpes drug 5-iodo-dUrd (Idoxuridine) offered little, if any, protection. Al- though the precise mechanism of action of (E-54(2-bromovinyl)-dUrd and (E)-(2-iodovinyl)-dUrd remains to be established, preliminary findings indicate that they do not specifically act at the thymidylate synthetase step.
Idoxuridine (5-iodo-2'-deoxyuridine) and trifluorothymidine (5-trifluoromethyl-2'-deoxyuridine) are among the best known antiviral agents currently used in the chemotherapy of-herpesvirus infections (1) . Their clinical usefulness is restricted to the topical treatment of local herpes simplex virus (HSV) infections such as herpetic keratitis and "cold sores" (herpes labialis). The unfavorable therapeutic index of Idoxuridine when administered parenterally-as most dramatically exemplified by its inefficacy in patients with herpes simplex encephalitis (2)-has prompted the search for more effective and less toxic anti-herpes agents. In recent years several compounds have been described which are all endowed with selective anti-herpes properties. These compounds include phosphonoacetic acid (3, 4) , phosphonoformic acid (5, 6), 9-f3-D-arabinofuranosyladenine (araA) (7, 8) , 5-iodo-5'-amino-2',5'-dideoxyuridine (AIDDU) (9, 10), 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine) (11, 12) , 1-f3-D-arabinofuranosylthymine (araT) (13, 14) , 5-iodo-and 5-bromo-2'-deoxycytidine (15, 16), 5,6-dihydro-5-azathymidine (17, 18) , and erythro-9-[3-(2-hydroxynonyl)]adenine (EHNA) (19) . Among the 5-substituted 2'-deoxyuridines, various compounds-namely, 5-methylamino-dUrd (20), 5-methoxymethyl-dUrd (21), 5-propyl-dUrd (22) , and 5-propynyloxy-dUrd (23)-proved more inhibitory to herpes than to any other DNA (or RNA) virus. We now report on the synthesis and antiviral potency of two new anti-herpes compounds, (E)-5-(2-bromovinyl)-dUrd and (E)-5-(2-iodoThe publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 vinyl)-dUrd. These compounds surpassed all previously described anti-herpes agents, including acycloguanosine, in both potency and selectivity, at least in primary rabbit kidney (PRK) cells infected with herpes simplex virus type 1 (HSV-1). Compounds 5-Vinyl-dUrd, 5-ethynyl-dUrd, (E)-5-(2-bromovinyl)-dUrd, and (E)-5-(2-iodovinyl)-dUrd were obtained by condensing the trimethylsilyl derivatives of the appropriate 5-substituted uracils with 2'-deoxy-3,5-di-0-p-toluoyl-a-D-erythropentofuranosyl chloride to give a mixture of the a-and f3-anomers of the protected nucleosides. T anomers were separated by chromatography on silica gel and the p-toluoyl protecting groups were removed by treatment with sodium methoxide in methanol. The results indicated for the biological experiments were all obtained by using the f3-anomers (Fig. 1) . The a-anomers were also tested for biological activity, but they were inactive. The synthesis of 5-ethynyl-dUrd and 5-vinyl-dUrd has been published (24, 25) . The synthesis of (E)-5-(2-bromovinyl)-dUrd, (E)-5-(2-iodovinyl)-dUrd, and 5-(1-chlorovinyl)-dUrd has been published elsewhere (ref. 26 and unpublished data). The structures assigned to these compounds were established by elemental analysis and UV and NMR spectroscopy.
The sources of the "standard" anti-herpes compounds were as follows: 5-iodo-dUrd, Ludeco (Brussels); 5-trifluoromethyl-dUrd, Sigma; phosphonoacetic acid, Abbott; acycloguanosine, Wellcome (Beckenham, England; courtesy of G. B. 
Antimetabolic activity
Nucleoside analogues that block dUrd incorporation into DNA at doses that are significantly lower than those required to inhibit dThd incorporation may be assumed to act specifically at the thymidylate synthetase level (29) . Indeed, the conversion of dUMP to dTMP is the only metabolic step that distinguishes the incorporation of dUrd and dThd into DNA dTMP. Accordingly, 5-ethynyl-dUrd and 5-(1-chlorovinyl)-dUrd, which suppressed dUrd incorporation into PRK cell DNA at concentrations that were not inhibitory for dThd incorporation (Table   1) , could be considered as selective thymidylate synthetase inhibitors. In this sense, they behaved like 5-fluoro-dUrd, 5-trifluoromethyl-dUrd, 5-nitro-dUrd, 5-cyano-dUrd, and 5-thiocyano-dUrd, which have also been recognized as selective thymidylate synthetase blockers (29) . The other 5-vinyl-dUrd analogues, (E)-5-(2-bromovinyl)-dUrd and (E)-5-(2-iodovinyl)-dUrd, and 5-vinyl-dUrd itself inhibited dUrd and dThd incorporation at nearly identical concentrations (Table 1) . These nucleoside analogues may be postulated to interfere with one (or more) stages of DNA biosynthesis other than the dTMP synthetase reaction.
Neither (E)-5-(2-bromovinyl)-dUrd nor (E)-5-(2-iodovinyl)-dUrd had an adverse effect on normal cell metabolism (as monitored by either dUrd or dThd incorporation into PRK cell DNA), unless a fairly high concentration (70 jg/ml) was used-that is, a 7000-to 10,000-fold higher concentration than that required to inhibit the replication of HSV-1 (KOS) ( Table  1) . Little, if any, selectivity was noted in the anti-herpes activity of 5-ethynyl-dUrd and 5-(1-chlorovinyl)-dUrd; these compounds inhibited normal cell metabolism (dUrd incorporation) at concentrations that coincided quite well with the antiviral doses ( Table 1) . That (E)-5-(2-bromovinyl)-dUrd could be considered as a highly selective anti-herpes agent was further attested by its failure to suppress normal (PRK) cell proliferation. Antiviral indexes, based on the ratio of the IDWo for total PRK cell counts to the ID50 for HSV-1 (KOS) replication, are listed in Table 1 . The anti-herpes index of (E)-5-(2-bromovinyl)-dUrd greatly exceeded those of 5-iodo-dUrd,5-(1-chlorovinyl)-dUrd, 5-ethynyl-dUrd, and 5-vinyl-dUrd (Table 1) . Relative potency and selectivity Because (E)-5-(2-bromovinyl)-dUrd and (E)-5-(2-iodovinyl)-dUrd appeared to be the most active and selective anti-herpes agents of the 5-vinyl-dUrd analogues (Table 1) , their relative potency and selectivity were compared to a wider variety of compounds with established anti-herpes potentials (see introduction). The antiviral activity was assessed with three different HSV-1 strains (KOS, F, and McIntyre), and both inhibition of dUrd incorporation into DNA and inhibition of cell growth were chosen as measures of cytotoxity. All tests were carried out with PRK cell cultures. Of all the compounds tested (Table  2) , (E)-5-(2-bromovinyl)-dUrd and (E)-5-(2-iodovinyl)-dUrd emerged as the most potent anti-herpes agents: in order of decreasing activity; (E)-5-(2-bromovinyl)-dUrd > (E)-5-(2-iodovinyl)-dUrd > acycloguanosine araC > 5-bromo-dCrd > 5-iodo-dUrd > araT > 5-trifluoromethyl-dUrd > 5-ethyl-dUrd > 5-propyl-dUrd > 5-propynyloxy-dUrd > araA > phosphonoacetate > AIDDU > EHNA. For some of these compounds a similar order of activity has been established in a previous study (12) : acycloguanosine > araC > 5-iodo-dUrd > trifluoromethyl-dUrd > araA > phosphonoacetate.
The minimum concentrations required for inhibition of cell growth were consistently higher than those required for inhibition of dUrd incorporation, and, in some instances, the minimum concentrations for cell growth inhibition could not be determined (Table 2 ). In general, the antiviral indexes, based on the ratio of the ID50 for dUrd incorporation to the IDso for HSV-1 replication, showed the same order as the antiviral indexes based on the ratio of the ID30 for total cell counts to the ID50 for HSV-1 replication (Table 2) . (E)-5-(2-Bromovinyl)-dUrd and (E)-5-(2-iodovinyl)-dUrd emerged as the most selective anti-herpes agents, followed by araT, 5-bromo-dCrd, 5-propyl-dUrd, and acycloguanosine. Somewhat less selective were 5-propynyloxy-dUrd and 5-ethyl-dUrd. Rather small. selectivity indexes were recorded for 5-iodo-dUrd, phosphonoacetate, and araA, whereas araC, AIDDU, EHNA, and 5-trifluoromethyl-dUrd revealed little, if any, selectivity in their anti-herpes action. 
Treatment of cutaneous herpes virus infection
Next, we examined the efficacy of (E)-5-(2-bromovinyl)-dUrd in a cutaneous HSV-1 model infection of athymic nude (nu/ nu) mice. This model is reminiscent of the experimental herpes skin infection of hairless mice (HRS/H strain) that has been used to evaluate the anti-herpes potentials of Kethoxal, 9-f3-D-arabinofuranosyladenine, 5,6-dihydroxy-5-azathymidine, and various other compounds (17, 32-34). As described previously for hairless mice (33, 35) , intracutaneous inoculation of nu/nu mice with HSV-1 (KOS) (on the midline of the spine) resulted in zoster-like skin lesions; the first symptoms to appear (usually on the fourth day after infection) were vesicles: these evolved to erosions which ulcerated and progressed downward from the site of inoculation to reach the midline of the abdomen by 6-8 days after inoculation (Fig. 3A) . After the sixth day after infection, control mice started to show symptoms of neurologic involvement and paralysis, which ultimately resulted in death.
When (E)-5-(2-bromovinyl)-dUrd or 5-iodo-dUrd was applied topically (at 1% in a water-soluble ointment), only (E)- Further details are described in the footnote to Table 3 .
5-(2-bromovinyl)-dUrd suppressed the development of cutaneous herpes lesions (Fig. 3B ) and prolonged the life span of the mice ( [16] [17] [18] g) were given (E)-5-(2-bromovinyl)-dUrd (600 mg/kg) intra- Table 3 . Effect of (E)-5-(2-bromovinyl)-dUrd and 5-iodo-dUrd on the incidence of herpetic skin lesions and mortality of nu/nu mice inoculated intracutaneously with HSV Mean survival Compound
No. of mice with epidermal lesion*/total no. of mice alive time, days Exp. 1 At day: Athymic nude (nu/nu) mice (25 days old), weighing [16] [17] [18] (1979) 2951 peritoneally over an 8-hr period. These mice developed normally and at 5 days after injection of the drug their body weight had increased by 24%, as had their placebo-treated counterparts. Mice that had been treated with 5-iodo-dUrd, however, did not develop normally, and 5 days after intraperitoneal injection of the drug (600 mg/kg) their body weight had increased by only 4%. Conclusions As a potential anti-herpes drug, (E)-5-(2-bromovinyl)-dUrd offers several advantages over the standard antiviral compound 5-iodo-dUrd:
(i) In PRK and HSF cell cultures, (E)-5-(2-bromovinyl)-dUrd was about 20 times more active [against the replication of HSV-1 (KOS)] and 60 times less toxic (as monitored by dUrd incorporation into DNA) than 5-iodo-dUrd; in its activity against HSV-1 in PRK cells, (E)-5-(2-bromovinyl)-dUrd exceeded various other established anti-herpes compounds, including phosphonoacetic acid, araA, AIDDU, and acycloguanosine in both potency and selectivity.
(ii) In animal model systems-namely, cutaneous herpes infections in athymnic nude mice-(E)-5-(2-bromovinyl)-dUrd suppressed the development of herpetic skin lesions and mortality therewith associated whether the drug was administered topically (as a 1% ointment) or systemically (at 60 mg/kg). The latter treatment was still efficacious when started at the time skin lesions (vesicles) had begun to develop (4 days after virus inoculation). When assayed under similar conditions, 5-iododUrd did not markedl' influence the course of the disease.
(iii) Blood drug levels obtained after intraperitoneal, subcutaneous, or oral administration of (E)-5-(2-bromovinyl)-dUrd to mice were significantly higher than those achieved with 5-iodo-dUrd. Active serum drug concentrations persisted for at least 5 hr if (E)-5-(2-bromovinyl)-dUrd was administered orally (unpublished data).
Whether (E)-5-(2-bromovinyl)-dUrd, like 5-iodo-dUrd and some other dUrd derivatives, is incorporated into viral or cellular DNA or both has not been determined. Unlike 5-iododUrd, (E)-5-(2-bromovinyl)-dUrd does not activate the release of oncornavirus (RNA tumor virus) particles from nonproducer cell lines such as BALB/c mouse cells (unpublished data).
The mode of action of (E)-5-(2-bromovinyl)-dUrd and the basis for its selective anti-herpes activity remain to be established. Whatever target (E)-5-(2-bromovinyl)-dUrd may act upon, its extremely high anti-herpes index in cell culture combined with its efficacy and apparent freedom of toxicity in animal model systems warrant further evaluation of the drug in those experimental and clinical infections in which the use of 5-iodo-dUrd would normally be indicated.
